TARS Tarsus Pharmaceuticals, Inc.
XNAS
77.90
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
What changed
Recent filings, trades and moves- 52-Week Range
- $53.89 – $91.53
- YTD
- -3.55%
- IV Rank (30D)
- 48.77
- Straddle Price
- $10.85
- P/C Vol Ratio
- 0.74
- Market Cap
- $3.7B
- Open
- $75.73
- Day Range
- $75.61 – $78.08
- Volume
- 387,383
- Prev Close
- $75.95
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.12% |
| Beta vs SPY | 0.78 |
| Cost of Equity (CAPM) | 9.04% (VRP-adj) |
| WACC | 8.81% |
| Volatility Risk Premium | +30.1pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +28.3% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.10 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $0.0B |
| Return on Equity (TTM) | -675.5% |
| Book / Price | 3.0% |
| Gross Margin (TTM) | 93.2% |
| FCF Margin (TTM) | 4.8% |
| Debt / Equity | 0.70 |
| Quality Score | 2/6 — normal (10y DCF) |
| SMA 50 | $74.29 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $73.24 |
| Bollinger Width / SMA20 | 19.8% (drives anchor stability) |
| Net Debt | $-0.1B |
| Market Cap | $4B |
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $51.45 | 15% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 40.2× · 7 peers |
| Peer EV/EBITDA | n/a | 0% | median 19.7× · 8 peers |
| Peer P/B | $13.66 | 12% | median 6.1× · 8 peers |
| Peer P/S | $106.05 | 12% | median 6.6× · 8 peers |
| Market Anchor (SMA50) | $74.29 | 31% | stability 51% (BB-width) |
| Options Expected (B-L 30d) | $74.19 | 30% | 26 strikes · skew +0.19 |
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
- Exchange
- XNAS
- Market Cap
- $3.7B
- Employees
- 370
- List Date
- 2020-10-16
- CIK
- 0001819790
- Last Earnings
- Nov 3 after close · −4.9% vs ±15.0% expected
- Next Earnings
- ~Feb 22, 2027 (estimated)
- Headquarters
- Irvine, CA
- Homepage
- https://www.tarsusrx.com
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community…
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -9.83% | -17.34% | 9.29% | 35.12% | -2.52% | -20.09% | -0.90% |
| Feb | -6.19% | -14.58% | -1.02% | 32.16% | -17.84% | 14.55% | 1.18% |
| Mar | -12.39% | -11.89% | -17.95% | -1.62% | 20.25% | -9.40% | -5.50% |
| Apr | -6.71% | 6.45% | 18.70% | -12.33% | 6.11% | -9.41% | 0.47% |
| May | 4.39% | -1.79% | 10.05% | 1.45% | -14.61% | -6.63% | -1.19% |
| Jun | -18.76% | 6.96% | 5.92% | -16.70% | -7.62% | 6.80% | -3.90% |
| Jul | -22.17% | -0.07% | 27.23% | -13.99% | -2.93% | -2.66% | -2.43% |
| Aug | 17.94% | 0.52% | -4.16% | 15.71% | 43.54% | 21.07% | 15.77% |
| Sep | -15.52% | 11.60% | 6.66% | 25.68% | 1.43% | 6.16% | 6.00% |
| Oct | 28.10% | 8.35% | -18.35% | 37.78% | 20.00% | -0.81% | 12.51% |
| Nov | -5.84% | -6.19% | 13.92% | 10.89% | 14.57% | 4.29%* | 5.27% |
| Dec | -7.37% | -13.25% | 27.68% | 9.82% | 2.39% | -- | 3.85% |
| Total | -49.20% | -31.24% | 89.69% | 173.16% | 60.37% | -3.04% | 39.96% |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
LLM Stock Analysis Report
Executive Summary
Overall Assessment: NEUTRAL (Confidence Level: 6/10)
Key Drivers:
- Strong fundamental performance with low volatility
- Bullish sentiment from recent news headlines
- Technical indicators signal a potentially range-bound market
Primary Risks:
- Low earnings estimates could impact stock price
- Volatility may increase if market conditions change
Investment Thesis:
Tarsus (TARS) is a fundamentally strong company with a stable share price. Recent news headlines suggest bullish sentiment, which aligns with the technical indicators' neutral signal. The options market expects a moderate move by expiration, indicating potential for continued stability.
Recent News Sentiment Impact:
The recent news headlines have a positive overall sentiment, highlighting Tarsus's participation in investor conferences and product advancements. These events may contribute to the company's stable share price.
Technical Analysis
Trend Direction: NEUTRAL (Short-term: range-bound, Medium-term: uptrend, Long-term: uptrend)
Support/Resistance Levels:
- Lower Bollinger Band: $59.36
- Middle Bollinger Band: $62.84
- Upper Bollinger Band: $66.33
Momentum Signals:
- RSI: 45.59 (neutral)
- MACD: -0.88 / Signal: 0.26 / Histogram: -1.14 (bearish)
Volume Analysis:
- Volume SMA 20: 742038.55
- On-Balance Volume (OBV): 12628526.74
- Volume Rate of Change: -74.17%
News & Sentiment Analysis
Recent Headlines Summary:
Tarsus's recent news headlines are primarily positive, highlighting the company's participation in investor conferences and product advancements.
Sentiment Assessment: POSITIVE
Catalyst Identification:
Upcoming earnings reports may impact stock price.
Market Narrative:
The news headlines align with the technical indicators' neutral signal, indicating a potentially range-bound market.
Risk & Volatility Assessment
Risk Interpretation: LOW (Beta: 0.79, Alpha: 0.27)
Volatility Regime: LOW (Stock Volatility: 0.44)
Options Market Signals:
- IV Rank: 19.4% (Low)
- Current IV: 73.5%
- Expected Move: $7.75 (27 DTE), 7-DTE: $7.75
- Volume Flow: 253 calls vs 13 puts
- Open Interest: 254 calls vs 1,166 puts
- Put/Call Volume Ratio: 0.05 (Bullish sentiment)
Downside Protection:
Support levels are in place at the lower Bollinger Band ($59.36), providing some downside protection.
Market Context & Positioning
Sector Performance:
Tarsus is performing relatively well within its sector, with a strong fundamental performance and low volatility.
Institutional Activity:
Volume patterns suggest institutional interest in Tarsus.
Correlation Analysis:
The stock moves relatively less than the market (R-squared interpretation), indicating a potentially defensive position.
Relative Valuation:
Tarsus's current price is relatively stable within its trading range, indicating a potentially neutral positioning.
Key Levels & Action Items
Critical Price Levels:
- Lower Bollinger Band: $59.36
- Middle Bollinger Band: $62.84
- Upper Bollinger Band: $66.33
Breakout/Breakdown Levels:
- SMA 20: $62.84 (support)
- SMA 50: $65.87 (resistance)
Time-Sensitive Catalysts:
Earnings reports may impact stock price.
Risk Management:
Stop-loss levels and position sizing considerations should be based on the recent range-bound market conditions.
Please note that this report is intended for educational purposes only and does not constitute investment advice or recommendations.
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2023-03-13 | After-Close | 41.72% | 0.85% | 0.02x | Within |
| 2023-05-09 | After-Close | 16.16% | 3.79% | 0.23x | Within |
| 2023-11-09 | After-Close | 36.48% | 12.20% | 0.33x | Within |
| 2024-02-27 | After-Close | 14.30% | 3.44% | 0.24x | Within |
| 2024-05-08 | After-Close | 18.07% | 8.86% | 0.49x | Within |
| 2024-08-08 | After-Close | 18.00% | 13.72% | 0.76x | Within |
| 2024-11-13 | After-Close | 23.38% | 0.31% | 0.01x | Within |
| 2025-02-25 | Pre-Market | 18.23% | 9.33% | 0.51x | Within |
| 2025-05-01 | Pre-Market | 14.79% | 3.10% | 0.21x | Within |
| 2025-08-06 | After-Close | 17.23% | 15.15% | 0.88x | Within |
| 2025-11-04 | After-Close | 15.03% | 4.62% | 0.31x | Within |
| 2026-02-23 | After-Close | 17.60% | 7.79% | 0.44x | Within |
| 2026-05-06 | After-Close | 15.75% | 1.24% | 0.08x | Within |
| 2026-08-05 | Pre-Market | 12.52% | 0.29% | 0.02x | Within |
| 2026-11-03 | After-Close | 15.01% | 4.91% | 0.33x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
TARS Options Activity & IV Rank
TARS IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Options Flow · All expiries
ATM Options Pricing
Chain Summary
TARS Implied Volatility
Loading implied volatility…
The 30-day IV is the at-the-money implied volatility of options 30 days out, the blue line. The band is its 20-session average, 2 standard deviations either side. Realized volatility is how much TARS actually moved over the last 20 sessions, from closing prices, on the same yearly scale. Without earnings takes each earnings report out of the 30-day IV, sized from what options paid for past reports, so it shows whether options are expensive or cheap apart from the report. Click a name above the chart to show or hide it.
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Estimated net dealer gamma is at the 80th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
IV(call wing) − IV(ATM), in vol pointsThe same measure on the upside: how the OTM call is priced against the at-the-money strike.
- Negative (typical) — calls trade below ATM for most stocks and indices, so the sign alone says little.
- Percentile vs own history: high = upside calls unusually rich for this name (squeezes, takeover talk, commodity supply scares); low = calls cheaper than usual.
Put or call vs ATM tells you how expensive that tail is. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Loading the implied volatility surface…
Loading the implied volatility smile…
Risk Metrics
Analysis Details
Data Points: 251
Period: 252 trading days
Low volatility - stock moves less than market
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Millennium Management Hedge fund Izzy Englander | $89.8M | #371 of 3716 | +152.8% | 13F | |
| Citadel Hedge fund Ken Griffin | $15.2M | #1302 of 6285 | +47.4% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $5.7M | #1380 of 3151 | +675.3% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $111K | #2996 of 4858 | +0.6% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
TARS Institutional Ownership (13F)
Filings for 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $11.86M | 41.37% | 2026-06-30 |
| 2 | Jane Street Group, LLC Custodian | $7.93M | 27.66% | 2026-09-30 |
| 3 | TORONTO DOMINION BANK | $2.96M | 10.31% | 2026-06-30 |
| 4 | GROUP ONE TRADING LLC Custodian | $2.34M | 8.17% | 2026-09-30 |
| 5 | Millennium Management LLC Custodian | $1.89M | 6.58% | 2026-06-30 |
| 6 | Citadel Advisors LLC Custodian | $1.37M | 4.76% | 2026-06-30 |
| 7 | Belvedere Trading LLC | $235.83K | 0.82% | 2026-09-30 |
| 8 | Simplex Trading, LLC Custodian | $94.33K | 0.33% | 2026-09-30 |
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Caption Management, LLC | $25.81M | 69.01% | 2026-06-30 |
| 2 | GROUP ONE TRADING LLC Custodian | $4.72M | 12.61% | 2026-09-30 |
| 3 | Susquehanna International Group, LLP Custodian | $2.83M | 7.57% | 2026-06-30 |
| 4 | Jane Street Group, LLC Custodian | $2.41M | 6.43% | 2026-09-30 |
| 5 | Simplex Trading, LLC Custodian | $801.82K | 2.14% | 2026-09-30 |
| 6 | Citadel Advisors LLC Custodian | $673.46K | 1.80% | 2026-06-30 |
| 7 | Belvedere Trading LLC | $157.22K | 0.42% | 2026-09-30 |
TARS Insider Trading (Form 4)
Latest: 2026-11-17| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-11-17 | Bobak R. Azamian | President/CEO and Board Chair | Sell (S) | −10,000 | $80.31 | -$803.1K | EDGAR |
| 2026-11-05 | Neera Clase | Chief Commercial Officer | Grant (A) | +17,265 opt | — | EDGAR | |
| 2026-09-17 | Wendy L Yarno | Director | Exer (M) | +302 | — | EDGAR | |
| 2026-09-17 | David E I Pyott | Director | Exer (M) | +201 | — | EDGAR | |
| 2026-09-17 | William J Phd Link | Director | Mixed Sell −12,500 · Exer +201 |
−12,299 | $78.38 | -$979.7K | EDGAR |
| 2026-09-09 | Elizabeth Yeu Lin | Chief Medical Officer | Sell (S) | −13,953 | $87.50 | -$1.22M | EDGAR |
| 2026-09-09 | Bobak R. Azamian | President/CEO and Board Chair | Sell (S) | −10,000 | $90.56 | -$905.6K | EDGAR |
| 2026-09-09 | Seshadri Neervannan | Chief Operating Officer | Sell (S) | −4,564 | $85.00 | -$387.9K | EDGAR |
| 2026-09-03 | Bobak R. Azamian | President/CEO and Board Chair | Sell (S) | −10,000 | $80.06 | -$800.6K | EDGAR |
| 2026-09-03 | Elizabeth Yeu Lin | Chief Medical Officer | Sell (S) | −11,578 | $77.56 | -$898.0K | EDGAR |
| 2026-06-29 | Bhaskar Chaudhuri | Director | Grant (A) | +6,254 RSU | — | EDGAR | |
| 2026-06-29 | Scott W Morrison | Director | Grant (A) | +6,254 RSU | — | EDGAR | |
| 2026-06-29 | David E I Pyott | Director | Grant (A) | +7,060 RSU | — | EDGAR | |
| 2026-06-29 | Katherine Goodrich | Director | Grant (A) | +6,254 opt | — | EDGAR | |
| 2026-06-29 | Andrew D. Goldberg | Director | Grant (A) | +6,254 opt | — | EDGAR |
TARS Insider Holdings
14 insiders · @ $77.06| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Bobak R. Azamian | President/CEO and Board Chair | 851,412 | $65.61M | -$15.84M | 66 | 2026-11-17 |
| 2 | William J Phd Link | Director | 94,487 | $7.28M | -$6.94M | 22 | 2026-09-17 |
| 3 | Seshadri Neervannan | Chief Operating Officer | 79,007 | $6.09M | -$2.54M | 18 | 2026-09-09 |
| 4 | Bryan Wahl | General Counsel | 63,959 | $4.93M | -$1.67M | 17 | 2026-03-19 |
| 5 | Aziz Mottiwala | Chief Commercial Officer | 61,480 | $4.74M | -$2.87M | 24 | 2026-03-19 |
| 6 | Jeffrey S Farrow | See Remarks | 56,801 | $4.38M | -$2.33M | 11 | 2026-06-17 |
| 7 | Dianne C. Whitfield | Chief Human Resources Officer | 35,028 | $2.70M | -$3.36M | 19 | 2026-03-19 |
| 8 | Andrew D. Goldberg | Director | 19,654 | $1.51M | $19.0K | 11 | 2026-06-29 |
| 9 | Wendy L Yarno | Director | 16,956 | $1.31M | $0 | 13 | 2026-09-17 |
| 10 | Elizabeth Yeu Lin | Chief Medical Officer | 16,177 | $1.25M | -$1.95M | 18 | 2026-09-09 |
TARS Board & Officers
As of SEC filings through Nov 17, 2026Directors 8
- Andrew D. Goldberg · since Oct 15, 2020
- Bhaskar Chaudhuri · since Oct 15, 2020
- Bobak R. Azamian · since Oct 15, 2020
- William J Phd Link · since Oct 15, 2020
- Wendy L Yarno · since Nov 19, 2020
- Scott W Morrison · since Oct 6, 2022
- Katherine Goodrich · since Nov 13, 2024
- David E I Pyott · since Feb 18, 2026
Officers 8
- Bobak R. Azamian · President/CEO and Board Chair · listed since Dec 2022
- Jeffrey S Farrow · Chief Financial Officer and Chief Strategy Officer · listed since Mar 2024
- Seshadri Neervannan · Chief Operating Officer · since Oct 15, 2020
- Aziz Mottiwala · Chief Commercial Officer · since Oct 15, 2020
- Dianne C. Whitfield · Chief Human Resources Officer · since Jan 7, 2021
- Elizabeth Yeu Lin · Chief Medical Officer · listed since Nov 2024
- Neera Clase · Chief Commercial Officer · since Nov 1, 2026
- Bryan Wahl · General Counsel · since Jan 19, 2021
Changes in the last 10 years (54)
| Nov 1, 2026 | Neera Clase became Chief Commercial Officer |
| Feb 18, 2026 | David E I Pyott became a director |
| Jan 15, 2025 | The company announced the departure of Rosemary A Crane from the board in an SEC filing |
| Nov 13, 2024 | Katherine Goodrich became a director |
| Nov 6, 2024 | Elizabeth Yeu Lin no longer listed as a director in SEC filings |
| Nov 6, 2024 | Elizabeth Yeu Lin first listed as Chief Medical Officer in an SEC filing |
| Mar 11, 2024 | Jeffrey S Farrow listed as Chief Financial Officer and Chief Strategy Officer (previously Chief Financial Officer and Chief Strategic Officer) in SEC filings |
| Apr 24, 2023 | Jeffrey S Farrow became Chief Financial Officer and Chief Strategic Officer |
| Mar 21, 2023 | Mark J. Holdbrook reported in an SEC filing no longer being V.P., Clinical Affairs |
| Dec 16, 2022 | Bobak R. Azamian listed as President/CEO and Board Chair (previously President and CEO) in SEC filings |
| Dec 1, 2022 | The company announced the departure of Michael Ackermann from the board in an SEC filing |
| Oct 6, 2022 | Scott W Morrison became a director |
| May 5, 2022 | Vivo Capital IX, LLC reported in an SEC filing no longer being a 10% owner |
| May 5, 2022 | Vivo Capital Fund IX, L.P. reported in an SEC filing no longer being a 10% owner |
| Feb 1, 2022 | Jose M. Trevejo became Chief Medical Officer |
| Dec 31, 2021 | Elizabeth Yeu Lin became a director |
| Aug 11, 2021 | Rosemary A Crane became a director |
| Jun 17, 2021 | Michael Ackermann no longer listed as a 10% owner in SEC filings |
| May 7, 2021 | Rtw Investments, LP reported in an SEC filing no longer being a 10% owner |
| May 7, 2021 | Roderick Wong reported in an SEC filing no longer being a 10% owner |
| Jan 19, 2021 | Bryan Wahl became General Counsel |
| Jan 8, 2021 | Bobak R. Azamian no longer listed as a 10% owner in SEC filings |
| Jan 7, 2021 | Dianne C. Whitfield became Chief Human Resources Officer |
| Nov 19, 2020 | Wendy L Yarno became a director |
| Oct 20, 2020 | Patrick J Heron reported in an SEC filing no longer being a 10% owner |
| Oct 20, 2020 | James N Topper reported in an SEC filing no longer being a 10% owner |
| Oct 20, 2020 | Horowitz Limited Partnership VIII reported in an SEC filing no longer being a 10% owner |
| Oct 20, 2020 | Frazier Life Sciences IX, L.P. reported in an SEC filing no longer being a 10% owner |
| Oct 20, 2020 | Fhmls Ix, L.p. reported in an SEC filing no longer being a 10% owner |
| Oct 20, 2020 | Fhmls Ix, L.l.c. reported in an SEC filing no longer being a 10% owner |
| Oct 16, 2020 | Rtw Investments, LP became a 10% owner |
| Oct 16, 2020 | Roderick Wong became a 10% owner |
| Oct 15, 2020 | William J Phd Link became a director |
| Oct 15, 2020 | Vivo Capital IX, LLC became a 10% owner |
| Oct 15, 2020 | Vivo Capital Fund IX, L.P. became a 10% owner |
| Oct 15, 2020 | Seshadri Neervannan became Chief Operating Officer |
| Oct 15, 2020 | Patrick J Heron became a 10% owner |
| Oct 15, 2020 | Michael Ackermann became a director |
| Oct 15, 2020 | Michael Ackermann became a 10% owner |
| Oct 15, 2020 | Mark J. Holdbrook became V.P., Clinical Affairs |
| Oct 15, 2020 | Leonard M. Greenstein became Chief Financial Officer |
| Oct 15, 2020 | Jason E. Tester became a director |
| Oct 15, 2020 | Jason E. Tester became a 10% owner |
| Oct 15, 2020 | James N Topper became a 10% owner |
| Oct 15, 2020 | Horowitz Limited Partnership VIII became a 10% owner |
| Oct 15, 2020 | Frazier Life Sciences IX, L.P. became a 10% owner |
| Oct 15, 2020 | Fhmls Ix, L.p. became a 10% owner |
| Oct 15, 2020 | Fhmls Ix, L.l.c. became a 10% owner |
| Oct 15, 2020 | Bobak R. Azamian became a director |
| Oct 15, 2020 | Bobak R. Azamian became a 10% owner |
| Oct 15, 2020 | Bobak R. Azamian became President and CEO |
| Oct 15, 2020 | Bhaskar Chaudhuri became a director |
| Oct 15, 2020 | Aziz Mottiwala became Chief Commercial Officer |
| Oct 15, 2020 | Andrew D. Goldberg became a director |
- Prev
- 1
Not reported recently (3)
- Jose M. Trevejo · Last reported as Chief Medical Officer in an SEC filing dated Dec 22, 2023
- Leonard M. Greenstein · Last reported as Chief Financial Officer in an SEC filing dated Apr 21, 2023
- Jason E. Tester · Last reported as a director in an SEC filing dated Jun 17, 2021
TARS Proposed Insider Sales (Form 144)
Latest: 2026-11-13What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-11-13 | Bobak Azamian | Officer | 10,000 | $801.5K | 2026-11-13 | Merrill Lynch | 10b5-1 | EDGAR |
| 2026-09-15 | WILLIAM J LINK | DIRECTOR | 12,500 | $979.7K | 2026-09-15 | MERRILL LYNCH | 10b5-1 | EDGAR |
| 2026-09-04 | Lin Elizabeth Yeu | Member of immediate family of any of the foregoing | 3,180 | $278.2K | 2026-09-04 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-09-04 | Lin Elizabeth Yeu | Officer | 10,773 | $942.6K | 2026-09-04 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-09-04 | Neervannan Seshadri | Officer | 4,564 | $387.9K | 2026-09-04 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-09-04 | BOBAK AZAMIAN | OFFICER | 10,000 | $905.6K | 2026-09-04 | MERRILL LYNCH | 10b5-1 | EDGAR |
| 2026-09-01 | Mottiwala Aziz | Former Officer | 77,698 | $5.75M | 2026-09-01 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-09-01 | Lin Elizabeth Yeu | Officer | 4,601 | $339.8K | 2026-09-01 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-08-25 | Mottiwala Aziz | Former Officer | 81,332 | $5.84M | 2026-08-25 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-08-19 | Mottiwala Aziz | Former Officer | 53,043 | $3.82M | 2026-08-19 | Fidelity Brokerage Services LLC | — | EDGAR |
| Filing Date | Event | Link |
|---|---|---|
| 2026-11-03 | Earnings results | EDGAR |
| 2026-09-10 | Acquisition or sale completed · Other events | EDGAR |
| 2026-08-06 | Earnings results | EDGAR |
| 2026-08-06 | Material agreement · Unregistered share sale · Other events | EDGAR |
| 2026-08-06 | Material agreement · Unregistered share sale · Other events | EDGAR |
| 2026-07-13 | Director or officer change | EDGAR |
| 2026-07-08 | Material agreement · Unregistered share sale · Other events | EDGAR |
| 2026-06-29 | Shareholder vote results | EDGAR |
| Filing Date | Accession | Link |
|---|
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | FBT First Trust NYSE® Arca® Biotechnology Index Fund | First Trust | 3.55% | $105.6M | $3.0B | 2026-11-17 |
| 2 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.11% | $85.6M | $75.0B | 2026-11-17 |
| 3 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $83.4M | — | 2026-10-31 |
| 4 | VXF Vanguard Extended Market ETF | Vanguard | 0.04% | $32.8M | — | 2026-10-31 |
| 5 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.23% | $30.9M | $13.5B | 2026-11-17 |
| 6 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.26% | $28.6M | $10.9B | 2026-11-17 |
| 7 | PJP Invesco Pharmaceuticals ETF | Invesco | 3.36% | $20.2M | — | 2026-11-17 |
| 8 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.10% | $18.4M | — | 2026-10-31 |
| 9 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.06% | $14.0M | — | 2026-08-31 |
| 10 | IHE iShares U.S. Pharmaceuticals ETF | iShares (BlackRock) | 0.63% | $10.7M | $1.7B | 2026-11-17 |
| 11 | XPH State Street® SPDR® S&P® Pharmaceuticals ETF | SPDR (State Street) | 2.00% | $10.2M | $507.9M | 2026-11-17 |
| 12 | FYC First Trust Small Cap Growth AlphaDEX® Fund | First Trust | 0.53% | $7.1M | $1.3B | 2026-11-17 |
| 13 | VHT Vanguard Health Care ETF | Vanguard | 0.03% | $6.9M | — | 2026-10-31 |
| 14 | SMLF iShares U.S. Small-Cap Equity Factor ETF | iShares (BlackRock) | 0.13% | $5.4M | $4.1B | 2026-11-17 |
| 15 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.00% | $4.3M | $93.0B | 2026-11-17 |
| 16 | SBIO ALPS Medical Breakthroughs ETF | Nport | 1.64% | $3.9M | — | 2026-08-31 |
| 17 | VTWG Vanguard Russell 2000 Growth ETF | Vanguard | 0.21% | $3.4M | — | 2026-10-31 |
| 18 | FYX First Trust Small Cap Core AlphaDEX® Fund | First Trust | 0.25% | $3.4M | $1.3B | 2026-11-17 |
| 19 | GSSC Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF | Goldman | 0.21% | $2.2M | $1.0B | 2026-11-17 |
| 20 | HAPS Harbor Human Capital Factor US Small Cap ETF | Nport | 1.03% | $1.7M | — | 2026-07-31 |
| 21 | SCHB Schwab U.S. Broad Market ETF | Nport | 0.00% | $1.7M | — | 2026-08-31 |
| 22 | ESML iShares ESG Aware MSCI USA Small-Cap ETF | iShares (BlackRock) | 0.06% | $1.6M | $2.7B | 2026-11-17 |
| 23 | RSSL Global X Russell 2000 ETF | Global X | 0.11% | $1.5M | — | 2026-11-18 |
| 24 | BBP Virtus Biotech Etf | Nport | 1.31% | $1.3M | — | 2026-07-31 |
| 25 | FHLC Fidelity MSCI Health Care Index ETF | Fidelity | 0.03% | $1.2M | $4.1B | 2026-11-17 |
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q3 '26 | 2026-09-30 | $194.57M | $-668.33M | $-14.40 | $-6.00M |
| Q2 '26 | 2026-06-30 | $173.91M | $-18.55M | $-0.43 | $61.22M |
| Q1 '26 | 2026-03-31 | $162.05M | $-7.65M | $-0.16 | $-24.65M |
| Q4 '25 | 2025-12-31 | $151.67M | $-8.17M | $-0.19 | $19.33M |
| Q3 '25 | 2025-09-30 | $118.70M | $-12.59M | $-0.30 | $18.26M |
| Q2 '25 | 2025-06-30 | $102.66M | $-20.34M | $-0.48 | $-29.39M |
| Q1 '25 | 2025-03-31 | $78.33M | $-25.21M | $-0.64 | $-20.65M |
| Q4 '24 | 2024-12-31 | $66.41M | $-22.93M | $-0.59 | $-22.18M |
| Q3 '24 | 2024-09-30 | $48.12M | $-23.42M | $-0.61 | $-8.65M |
| Q2 '24 | 2024-06-30 | $40.81M | $-33.29M | $-0.88 | $-14.40M |
| Q1 '24 | 2024-03-31 | $27.61M | $-35.73M | $-1.01 | $-37.79M |
| Q4 '23 | 2023-12-31 | $13.08M | $-41.90M | $-1.27 | $-39.34M |
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
TARS vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| LLY Eli Lilly & Co. | $1.23T | 44.0 | +45.5% | +25.6% | 36 |
| JNJ Johnson & Johnson | $656.5B | 40.6 | +7.8% | +28.9% | 88 |
| AMGN Amgen Inc | $240.1B | 25.6 | +8.2% | +34.6% | 43 |
| GILD Gilead Sciences Inc | $209.6B | — | +6.5% | +37.8% | 59 |
| PFE Pfizer Inc. | $159.9B | 39.6 | +1.3% | +10.1% | 77 |
| REGN Regeneron Pharmaceuticals Inc | $97.8B | 20.7 | +18.6% | +20.9% | 66 |
| BIIB Biogen Inc. Common Stock | $37.2B | 106.0 | +2.3% | +39.4% | 100 |
| UTHR United Therapeutics Corp | $24.6B | 21.3 | +1.9% | +13.4% | 24 |
| TARS Tarsus Pharmaceuticals, Inc. Common Stoc | $3.7B | — | +86.3% | −4.6% | 47 |
| Peer median | $184.8B | 39.6 | +7.2% | +27.3% | 63 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.